{
    "organizations": [],
    "uuid": "940cbb16c7577751aee42a3c1bb10532820681db",
    "author": "",
    "url": "https://www.reuters.com/article/brief-cara-therapeutics-initiates-pivota/brief-cara-therapeutics-initiates-pivotal-phase-3-efficacy-trial-of-korsuva-injection-idUSASB0C36Y",
    "ord_in_thread": 0,
    "title": "BRIEF-Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial Of Korsuva Injection",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 31, 2018 / 12:04 PM / in 9 minutes BRIEF-Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial Of Korsuva Injection Reuters Staff 1 Min Read \nJan 31 (Reuters) - Cara Therapeutics Inc: \n* CARA THERAPEUTICS INITIATES PIVOTAL PHASE 3 EFFICACY TRIAL OF KORSUVAâ„¢ (CR845/DIFELIKEFALIN) INJECTION IN HEMODIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS Source text for Eikon: Further company coverage:",
    "published": "2018-01-31T14:04:00.000+02:00",
    "crawled": "2018-01-31T14:16:04.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "therapeutic",
        "initiate",
        "pivotal",
        "phase",
        "efficacy",
        "trial",
        "korsuva",
        "injection",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "cara",
        "therapeutic",
        "inc",
        "cara",
        "therapeutic",
        "initiate",
        "pivotal",
        "phase",
        "efficacy",
        "trial",
        "injection",
        "hemodialysis",
        "patient",
        "chronic",
        "kidney",
        "pruritus",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}